痴呆
阶段（地层学）
食品药品监督管理局
认知障碍
疾病
医学
阿尔茨海默病
载脂蛋白E
老年学
内科学
药理学
生物
古生物学
作者
Hai V. Nguyen,Shweta Mital,David S. Knopman,Emily Han-Chung Hsiue
出处
期刊：Neurology
[Ovid Technologies (Wolters Kluwer)]
日期：2024-03-14
卷期号：102 (7)
被引量：8
标识
DOI：10.1212/wnl.0000000000209218
摘要
Little is known regarding the cost-effectiveness of lecanemab (Leqembi), a monoclonal antibody approved by the US Food and Drug Administration in January 2023 for the treatment of mild cognitive impairment (MCI) or mild dementia due to Alzheimer disease (AD). This study aims to quantify the cost-effectiveness of lecanemab and how it varies based on the accuracy of AD testing and individuals' APOE ε4 status.
科研通智能强力驱动
Strongly Powered by AbleSci AI
嗯哼
无忧
坚强的广山
热心市民小红花
Singularity
张三坟
kento
shinysparrow
李神奇
吃不饱星球球长
Ally
张思梦
从容芮
豆子
毛豆爸爸
xiaoyun2852
寻道图强
rosalieshi
8R60d8
Frank
皖公网安备34019202002308
